PeptideInfo
العربيةGet the app
☰
Metabolic researchHuman RCTApproved (US)

Semaglutide

Ozempic · Wegovy · Rybelsus

Semaglutide activates GLP1R and shares 94% sequence homology with native GLP-1. Receptor activation slows stomach emptying, reduces glucagon secretion and promotes insulin release in a glucose-dependent manner. Signaling through hypothalamic GLP-1 receptors reduces appetite. Structural modifications promote albumin binding and support a half-life of seven days.

Not medical advice. Educational reference only.

Typical dose
0.25 mg, once weekly, subcutaneous injection; 0.5 mg, once weekly, subcutaneous injection; 1 mg, once weekly, subcutaneous injection; 2.4 mg, once weekly, subcutaneous injection
Route
Subcutaneous injection; Oral (Rybelsus)
Storage
Keep refrigerated at 2–8°C and use within 28 days.

What is Semaglutide?

Semaglutide is a Novo Nordisk GLP-1 receptor agonist. US approvals include Ozempic for type 2 diabetes in 2017, oral daily Rybelsus in 2019, and Wegovy for chronic weight management in 2021. In STEP 1, a weekly 2.4 mg dose produced mean weight loss of 14.9% over 68 weeks. The 2023 SELECT trial found a 20% reduction in major cardiovascular events. Ozempic and Wegovy use weekly injections; Rybelsus is a daily tablet.

Mechanism of action

Semaglutide activates GLP1R and shares 94% sequence homology with native GLP-1. Receptor activation slows stomach emptying, reduces glucagon secretion and promotes insulin release in a glucose-dependent manner. Signaling through hypothalamic GLP-1 receptors reduces appetite. Structural modifications promote albumin binding and support a half-life of seven days.

Targets: GLP-1 receptor

Research indications

  • Weight Loss

    Most effective

    Clinical trials show substantial reductions in body weight with benefits that persist over follow-up.

    Human, randomised1 reference

  • Blood Sugar Control

    Most effective

    Research examines improved glucose regulation and reduced A1C in people with type 2 diabetes.

  • Cardiovascular Health

    Effective

    Research addresses fewer cardiovascular events among people at elevated risk.

    Human, randomised1 reference

  • Metabolic Syndrome

    Effective

    Potential metabolic benefits involve several components of metabolic syndrome at once.

Research protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalAmountFrequencyRoute
Starting Dose (Week 1–4)0.25 mgOnce weeklySubcutaneous injection
Dose escalation during weeks 5–80.5 mgOnce weeklySubcutaneous injection
Standard Diabetes Dose1 mgOnce weeklySubcutaneous injection
Weight Loss Maintenance2.4 mgOnce weeklySubcutaneous injection

Interactions

  • Other GLP-1 agonists (semaglutide, tirzepatide)

    Avoid

  • Insulin

    Monitor

  • Sulfonylureas

    Monitor

  • Metformin

    Compatible

  • SGLT2 Inhibitors

    Compatible

  • Oral Contraceptives

    Caution

  • Warfarin / Blood Thinners

    Monitor

  • NAD+

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water; avoid saline because it may cause precipitation.

  1. Warm the refrigerated semaglutide vial to room temperature for 15–20 minutes.
  2. Disinfect the vial’s rubber closure with an alcohol wipe, then wait until it has dried completely.
  3. Use a sterile syringe to measure the calculated amount of bacteriostatic water. Avoid saline because precipitation may occur.
  4. Add the water slowly against the vial’s inner wall. Keep the stream away from the dry powder itself.
  5. Swirl gently. Avoid forceful shaking, which can damage the peptide.
  6. Allow 2–3 minutes for dissolution. Check that the solution is clear and colorless.
  7. Measure your calculated subcutaneous dose with an insulin syringe after dissolution.
  8. Choose the abdomen, upper arm or thigh for injection. Alternate the injection location each time to help prevent lipodystrophy.
  9. Refrigerate the mixed research formulation at 2–8°C; discard it after 28 days. Follow product-specific instructions for prescription presentations.

What to expect

Week 1–2
Appetite may start to decline. Mild nausea or a sense of fullness can accompany the initial adjustment.
Week 2–4
Cravings and meal portions may become noticeably smaller, with the first changes in body weight.
Week 4–8
Appetite control may strengthen as weight declines steadily; glucose regulation may also improve when relevant.
Week 8–16
Larger weight changes and greater energy may develop, while metabolic measurements begin to improve.
Week 16–24
Further weight-loss milestones may coincide with cardiovascular benefits and improvements in lipid measurements.
Week 24+
Sustained benefit and broader metabolic improvements may develop toward maximal efficacy. Timing varies, and trial endpoints extend beyond this interval.

Side effects and safety

  • Nausea, usually dose-related, greatest during escalation and improving over time · Most common; 44%
  • Loose stools or constipation while increasing the dose · Diarrhea: 30%
  • Vomiting, especially during initiation or upward dose adjustments · 24%
  • Less appetite and feeling full earlier during meals
  • Bruising or redness around the injection area
  • Tiredness, particularly during the first weeks
  • Pancreatitis; stop use immediately if severe abdominal pain develops · Rare
  • Thyroid C-cell tumors in rodents; corresponding risk in humans remains unconfirmed · Rare
  • Gallbladder disease · Rare

Contraindications

  • Avoid use with a personal or family history of medullary thyroid carcinoma or MEN2.

Semaglutide: approved in the US.

Regulatory status

  • US

    Approved

    FDA — Prescription approvals include Ozempic for type 2 diabetes (2017), Rybelsus as a daily oral product (2019), and Wegovy for chronic weight management (2021).

    Rx required
    Yes
    Telehealth
    Available

Frequently asked questions

What average weight change occurred with semaglutide?

In STEP 1, weekly 2.4 mg semaglutide produced average weight loss of 14.9%, approximately 15.3 kg, over 68 weeks. Placebo participants lost 2.4%. Around half of treated participants lost at least 15% of their initial weight, while individual outcomes varied substantially. Lifestyle changes alongside medication help optimize results.

How soon do effects develop?

Appetite and cravings often decline during the first 1–2 weeks at the initial 0.25 mg dose. Weight reductions of 5–10% commonly emerge over weeks 8–16. At maintenance dosing, reductions of 14–22% can occur by 68 weeks or later. Increasing the dose over 4–5 months helps reduce adverse effects.

What are the prescription criteria?

A licensed clinician must prescribe semaglutide. Ozempic treatment requires a type 2 diabetes diagnosis. For obesity treatment with Wegovy, criteria include BMI of at least 30, or at least 27 together with a weight-related comorbidity. Prescription assessment is available through telehealth and weight-management clinics.

References

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity. (2021)

    PMID 33567185DOI 10.1056/NEJMoa2032183

  2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. (2023)

    PMID 37952131DOI 10.1056/NEJMoa2307563

  3. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. (2022)

    PMID 34514682DOI 10.1111/dom.14551

  4. WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information (2021)

  5. OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information (2017)

  6. Once-Weekly Semaglutide in Adolescents with Obesity. (2022)

    PMID 36322838DOI 10.1056/NEJMoa2208601

  7. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. (2023)

    PMID 37622681DOI 10.1056/NEJMoa2306963

  8. Semaglutide obesity studies on ClinicalTrials.gov (2024)